{
  "solution_stats": {
    "total_solutions": 4,
    "details": [
      {
        "solution_id": 1,
        "steps_count": 4
      },
      {
        "solution_id": 2,
        "steps_count": 6
      },
      {
        "solution_id": 3,
        "steps_count": 5
      },
      {
        "solution_id": 4,
        "steps_count": 5
      }
    ]
  },
  "solutions": [
    {
      "id": 1,
      "family_id": 1,
      "path_type": "core",
      "branch_from": null,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "MT",
          "premises_used": [
            {
              "id": "Rule18",
              "prover9": "(-(-(A2 -> (-G -> A1)) -> A3) -> A4)",
              "prover9_expression": "(-(-(passes_phase_3_trial(DrugX) -> (-is_viable_therapy(DrugX) -> receives_fda_approval(DrugX))) -> receives_emergency_use_authorization(DrugX)) -> receives_orphan_drug_status(DrugX))",
              "natural": "If the failure of DrugX passing phase 3 clinical trials to lead to the scenario where if DrugX is not a viable therapy then DrugX receives FDA approval does not result in DrugX receiving emergency use authorization, then DrugX receives orphan drug status."
            },
            {
              "id": "Fact6",
              "prover9": "-A4",
              "prover9_expression": "-receives_orphan_drug_status(DrugX)",
              "natural": "DrugX does not receive orphan drug status."
            }
          ],
          "conclusion": "(-(A2 -> (-G -> A1)) -> A3)",
          "natural": "If DrugX passing phase 3 clinical trials does not lead to the scenario where if DrugX is not a viable therapy then DrugX receives FDA approval, then DrugX receives emergency use authorization."
        },
        {
          "step_number": 2,
          "rule_applied": "RAA",
          "premises_used": [
            {
              "id": "Derived",
              "prover9": "(-(A2 -> (-G -> A1)) -> A3)",
              "prover9_expression": "(-(passes_phase_3_trial(DrugX) -> (-is_viable_therapy(DrugX) -> receives_fda_approval(DrugX))) -> receives_emergency_use_authorization(DrugX))",
              "natural": "If DrugX passing phase 3 clinical trials does not lead to the scenario where if DrugX is not a viable therapy then DrugX receives FDA approval, then DrugX receives emergency use authorization."
            },
            {
              "id": "Rule17",
              "prover9": "(-(A2 -> (-G -> A1)) -> -A3)",
              "prover9_expression": "(-(passes_phase_3_trial(DrugX) -> (-is_viable_therapy(DrugX) -> receives_fda_approval(DrugX))) -> -receives_emergency_use_authorization(DrugX))",
              "natural": "If DrugX passing phase 3 clinical trials does not lead to the scenario where if DrugX is not a viable therapy then DrugX receives FDA approval, then DrugX does not receive emergency use authorization."
            }
          ],
          "conclusion": "(A2 -> (-G -> A1))",
          "natural": "If DrugX passes phase 3 clinical trials, then if DrugX is not a viable therapy, then DrugX receives FDA approval."
        },
        {
          "step_number": 3,
          "rule_applied": "MP",
          "premises_used": [
            {
              "id": "Derived",
              "prover9": "(A2 -> (-G -> A1))",
              "prover9_expression": "(passes_phase_3_trial(DrugX) -> (-is_viable_therapy(DrugX) -> receives_fda_approval(DrugX)))",
              "natural": "If DrugX passes phase 3 clinical trials, then if DrugX is not a viable therapy, then DrugX receives FDA approval."
            },
            {
              "id": "Fact2",
              "prover9": "A2",
              "prover9_expression": "passes_phase_3_trial(DrugX)",
              "natural": "DrugX passes phase 3 clinical trials."
            }
          ],
          "conclusion": "(-G -> A1)",
          "natural": "If DrugX is not a viable therapy, then DrugX receives FDA approval."
        },
        {
          "step_number": 4,
          "rule_applied": "MT",
          "premises_used": [
            {
              "id": "Derived",
              "prover9": "(-G -> A1)",
              "prover9_expression": "(-is_viable_therapy(DrugX) -> receives_fda_approval(DrugX))",
              "natural": "If DrugX is not a viable therapy, then DrugX receives FDA approval."
            },
            {
              "id": "Fact4",
              "prover9": "-A1",
              "prover9_expression": "-receives_fda_approval(DrugX)",
              "natural": "DrugX does not receive FDA approval."
            }
          ],
          "conclusion": "G",
          "natural": "DrugX is a viable therapy."
        }
      ]
    },
    {
      "id": 2,
      "family_id": 2,
      "path_type": "core",
      "branch_from": null,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "CD",
          "premises_used": [
            {
              "id": "Rule1",
              "prover9": "(A11 -> A10)",
              "prover9_expression": "(treats_rare_disease(DrugX) -> gets_priority_review(DrugX))",
              "natural": "If DrugX treats a rare disease, then DrugX gets priority review status."
            },
            {
              "id": "Rule3",
              "prover9": "(A12 -> (-(-(A5 -> A7) -> A8) -> A9))",
              "prover9_expression": "(addresses_unmet_medical_need(DrugX) -> (-(-(demonstrates_clinical_efficacy(DrugX) -> meets_endpoints(DrugX)) -> requires_additional_studies(DrugX)) -> qualifies_for_fast_track(DrugX)))",
              "natural": "If DrugX addresses an unmet medical need, then if the failure of DrugX demonstrating clinical efficacy to lead to meeting endpoints does not result in DrugX requiring additional studies, then DrugX qualifies for fast track designation."
            },
            {
              "id": "Rule2",
              "prover9": "(A11 | A12)",
              "prover9_expression": "(treats_rare_disease(DrugX) | addresses_unmet_medical_need(DrugX))",
              "natural": "DrugX treats a rare disease or DrugX addresses an unmet medical need."
            }
          ],
          "conclusion": "(A10 | (-(-(A5 -> A7) -> A8) -> A9))",
          "natural": "DrugX gets priority review status, or if the failure of DrugX demonstrating clinical efficacy to lead to meeting endpoints does not result in DrugX requiring additional studies, then DrugX qualifies for fast track designation."
        },
        {
          "step_number": 2,
          "rule_applied": "DS",
          "premises_used": [
            {
              "id": "Derived",
              "prover9": "(A10 | (-(-(A5 -> A7) -> A8) -> A9))",
              "prover9_expression": "(gets_priority_review(DrugX) | (-(-(demonstrates_clinical_efficacy(DrugX) -> meets_endpoints(DrugX)) -> requires_additional_studies(DrugX)) -> qualifies_for_fast_track(DrugX)))",
              "natural": "DrugX gets priority review status, or if the failure of DrugX demonstrating clinical efficacy to lead to meeting endpoints does not result in DrugX requiring additional studies, then DrugX qualifies for fast track designation."
            },
            {
              "id": "Fact5",
              "prover9": "-A10",
              "prover9_expression": "-gets_priority_review(DrugX)",
              "natural": "DrugX does not get priority review status."
            }
          ],
          "conclusion": "(-(-(A5 -> A7) -> A8) -> A9)",
          "natural": "If the failure of DrugX demonstrating clinical efficacy to lead to DrugX meeting all clinical trial endpoints does not result in DrugX requiring additional clinical studies, then DrugX qualifies for fast track designation."
        },
        {
          "step_number": 3,
          "rule_applied": "MT",
          "premises_used": [
            {
              "id": "Derived",
              "prover9": "(-(-(A5 -> A7) -> A8) -> A9)",
              "prover9_expression": "(-(-(demonstrates_clinical_efficacy(DrugX) -> meets_endpoints(DrugX)) -> requires_additional_studies(DrugX)) -> qualifies_for_fast_track(DrugX))",
              "natural": "If the failure of DrugX demonstrating clinical efficacy to lead to DrugX meeting all clinical trial endpoints does not result in DrugX requiring additional clinical studies, then DrugX qualifies for fast track designation."
            },
            {
              "id": "Fact8",
              "prover9": "-A9",
              "prover9_expression": "-qualifies_for_fast_track(DrugX)",
              "natural": "DrugX does not qualify for fast track designation."
            }
          ],
          "conclusion": "(-(A5 -> A7) -> A8)",
          "natural": "If DrugX demonstrating clinical efficacy does not lead to DrugX meeting all clinical trial endpoints, then DrugX requires additional clinical studies."
        },
        {
          "step_number": 4,
          "rule_applied": "MT",
          "premises_used": [
            {
              "id": "Derived",
              "prover9": "(-(A5 -> A7) -> A8)",
              "prover9_expression": "(-(demonstrates_clinical_efficacy(DrugX) -> meets_endpoints(DrugX)) -> requires_additional_studies(DrugX))",
              "natural": "If DrugX demonstrating clinical efficacy does not lead to DrugX meeting all clinical trial endpoints, then DrugX requires additional clinical studies."
            },
            {
              "id": "Fact7",
              "prover9": "-A8",
              "prover9_expression": "-requires_additional_studies(DrugX)",
              "natural": "DrugX does not require additional clinical studies."
            }
          ],
          "conclusion": "(A5 -> A7)",
          "natural": "If DrugX demonstrates clinical efficacy, then DrugX meets all clinical trial endpoints."
        },
        {
          "step_number": 5,
          "rule_applied": "HS",
          "premises_used": [
            {
              "id": "Derived",
              "prover9": "(A5 -> A7)",
              "prover9_expression": "(demonstrates_clinical_efficacy(DrugX) -> meets_endpoints(DrugX))",
              "natural": "If DrugX demonstrates clinical efficacy, then DrugX meets all clinical trial endpoints."
            },
            {
              "id": "Rule16",
              "prover9": "(A7 -> G)",
              "prover9_expression": "(meets_endpoints(DrugX) -> is_viable_therapy(DrugX))",
              "natural": "If DrugX meets all clinical trial endpoints, then DrugX is a viable therapy."
            }
          ],
          "conclusion": "(A5 -> G)",
          "natural": "If DrugX demonstrates clinical efficacy, then DrugX is a viable therapy."
        },
        {
          "step_number": 6,
          "rule_applied": "DE",
          "premises_used": [
            {
              "id": "Rule14",
              "prover9": "(A5 | A6)",
              "prover9_expression": "(demonstrates_clinical_efficacy(DrugX) | shows_safety_profile(DrugX))",
              "natural": "DrugX demonstrates clinical efficacy or DrugX shows an acceptable safety profile."
            },
            {
              "id": "Derived",
              "prover9": "(A5 -> G)",
              "prover9_expression": "(demonstrates_clinical_efficacy(DrugX) -> is_viable_therapy(DrugX))",
              "natural": "If DrugX demonstrates clinical efficacy, then DrugX is a viable therapy."
            },
            {
              "id": "Rule15",
              "prover9": "(A6 -> G)",
              "prover9_expression": "(shows_safety_profile(DrugX) -> is_viable_therapy(DrugX))",
              "natural": "If DrugX shows an acceptable safety profile, then DrugX is a viable therapy."
            }
          ],
          "conclusion": "G",
          "natural": "DrugX is a viable therapy."
        }
      ]
    },
    {
      "id": 3,
      "family_id": 3,
      "path_type": "core",
      "branch_from": null,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "MP",
          "premises_used": [
            {
              "id": "Rule7",
              "prover9": "(A17 -> -A16)",
              "prover9_expression": "(faces_manufacturing_delay(DrugX) -> -becomes_available_to_patients(DrugX))",
              "natural": "If DrugX faces manufacturing delays, then DrugX does not become available to patients."
            },
            {
              "id": "Fact1",
              "prover9": "A17",
              "prover9_expression": "faces_manufacturing_delay(DrugX)",
              "natural": "DrugX faces manufacturing delays."
            }
          ],
          "conclusion": "-A16",
          "natural": "DrugX does not become available to patients."
        },
        {
          "step_number": 2,
          "rule_applied": "MT",
          "premises_used": [
            {
              "id": "Rule5",
              "prover9": "(A15 -> A16)",
              "prover9_expression": "(enters_production(DrugX) -> becomes_available_to_patients(DrugX))",
              "natural": "If DrugX enters commercial production, then DrugX becomes available to patients."
            },
            {
              "id": "Derived",
              "prover9": "-A16",
              "prover9_expression": "-becomes_available_to_patients(DrugX)",
              "natural": "DrugX does not become available to patients."
            }
          ],
          "conclusion": "-A15",
          "natural": "DrugX does not enter commercial production."
        },
        {
          "step_number": 3,
          "rule_applied": "DS",
          "premises_used": [
            {
              "id": "Rule6",
              "prover9": "(A15 | -A14)",
              "prover9_expression": "(enters_production(DrugX) | -attracts_investor_funding(DrugX))",
              "natural": "DrugX enters commercial production or DrugX does not attract investor funding."
            },
            {
              "id": "Derived",
              "prover9": "-A15",
              "prover9_expression": "-enters_production(DrugX)",
              "natural": "DrugX does not enter commercial production."
            }
          ],
          "conclusion": "-A14",
          "natural": "DrugX does not attract investor funding."
        },
        {
          "step_number": 4,
          "rule_applied": "DS",
          "premises_used": [
            {
              "id": "Rule4",
              "prover9": "(A14 | -A13)",
              "prover9_expression": "(attracts_investor_funding(DrugX) | -has_commercial_market(DrugX))",
              "natural": "DrugX attracts investor funding or DrugX does not have a viable commercial market."
            },
            {
              "id": "Derived",
              "prover9": "-A14",
              "prover9_expression": "-attracts_investor_funding(DrugX)",
              "natural": "DrugX does not attract investor funding."
            }
          ],
          "conclusion": "-A13",
          "natural": "DrugX does not have a viable commercial market."
        },
        {
          "step_number": 5,
          "rule_applied": "MT",
          "premises_used": [
            {
              "id": "Rule19",
              "prover9": "(-G -> A13)",
              "prover9_expression": "(-is_viable_therapy(DrugX) -> has_commercial_market(DrugX))",
              "natural": "If DrugX is not a viable therapy, then DrugX has a viable commercial market."
            },
            {
              "id": "Derived",
              "prover9": "-A13",
              "prover9_expression": "-has_commercial_market(DrugX)",
              "natural": "DrugX does not have a viable commercial market."
            }
          ],
          "conclusion": "G",
          "natural": "DrugX is a viable therapy."
        }
      ]
    },
    {
      "id": 4,
      "family_id": 4,
      "path_type": "core",
      "branch_from": null,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "MP",
          "premises_used": [
            {
              "id": "Rule13",
              "prover9": "(A23 -> A22)",
              "prover9_expression": "(conducts_real_world_evidence_study(DrugX) -> presents_health_economic_data(DrugX))",
              "natural": "If DrugX conducts real-world evidence study, then DrugX presents health economic data."
            },
            {
              "id": "Fact3",
              "prover9": "A23",
              "prover9_expression": "conducts_real_world_evidence_study(DrugX)",
              "natural": "DrugX conducts real-world evidence study."
            }
          ],
          "conclusion": "A22",
          "natural": "DrugX presents health economic data."
        },
        {
          "step_number": 2,
          "rule_applied": "MP",
          "premises_used": [
            {
              "id": "Rule12",
              "prover9": "(A22 -> (A19 -> A21))",
              "prover9_expression": "(presents_health_economic_data(DrugX) -> (demonstrates_cost_effectiveness(DrugX) -> gets_formulary_inclusion(DrugX)))",
              "natural": "If DrugX presents health economic data, then if DrugX demonstrates cost effectiveness, then DrugX gets formulary inclusion."
            },
            {
              "id": "Derived",
              "prover9": "A22",
              "prover9_expression": "presents_health_economic_data(DrugX)",
              "natural": "DrugX presents health economic data."
            }
          ],
          "conclusion": "(A19 -> A21)",
          "natural": "If DrugX demonstrates cost effectiveness, then DrugX gets formulary inclusion."
        },
        {
          "step_number": 3,
          "rule_applied": "HS",
          "premises_used": [
            {
              "id": "Derived",
              "prover9": "(A19 -> A21)",
              "prover9_expression": "(demonstrates_cost_effectiveness(DrugX) -> gets_formulary_inclusion(DrugX))",
              "natural": "If DrugX demonstrates cost effectiveness, then DrugX gets formulary inclusion."
            },
            {
              "id": "Rule11",
              "prover9": "(A21 -> -A18)",
              "prover9_expression": "(gets_formulary_inclusion(DrugX) -> -receives_insurance_coverage(DrugX))",
              "natural": "If DrugX gets formulary inclusion, then DrugX does not receive insurance coverage."
            }
          ],
          "conclusion": "(A19 -> -A18)",
          "natural": "If DrugX demonstrates cost effectiveness, then DrugX does not receive insurance coverage."
        },
        {
          "step_number": 4,
          "rule_applied": "DE",
          "premises_used": [
            {
              "id": "Rule9",
              "prover9": "(A19 | A20)",
              "prover9_expression": "(demonstrates_cost_effectiveness(DrugX) | shows_superiority_to_standard_care(DrugX))",
              "natural": "DrugX demonstrates cost effectiveness or DrugX shows superiority to standard care."
            },
            {
              "id": "Derived",
              "prover9": "(A19 -> -A18)",
              "prover9_expression": "(demonstrates_cost_effectiveness(DrugX) -> -receives_insurance_coverage(DrugX))",
              "natural": "If DrugX demonstrates cost effectiveness, then DrugX does not receive insurance coverage."
            },
            {
              "id": "Rule10",
              "prover9": "(A20 -> -A18)",
              "prover9_expression": "(shows_superiority_to_standard_care(DrugX) -> -receives_insurance_coverage(DrugX))",
              "natural": "If DrugX shows superiority to standard care, then DrugX does not receive insurance coverage."
            }
          ],
          "conclusion": "-A18",
          "natural": "DrugX does not receive insurance coverage."
        },
        {
          "step_number": 5,
          "rule_applied": "DS",
          "premises_used": [
            {
              "id": "Rule8",
              "prover9": "(A18 | G)",
              "prover9_expression": "(receives_insurance_coverage(DrugX) | is_viable_therapy(DrugX))",
              "natural": "DrugX receives insurance coverage or DrugX is a viable therapy."
            },
            {
              "id": "Derived",
              "prover9": "-A18",
              "prover9_expression": "-receives_insurance_coverage(DrugX)",
              "natural": "DrugX does not receive insurance coverage."
            }
          ],
          "conclusion": "G",
          "natural": "DrugX is a viable therapy."
        }
      ]
    }
  ]
}